UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2017-08, Vol.31 (4), p.299-316

2017

Volltextzugriff (PDF)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

Arthritis research & therapy, 2020-10, Vol.22 (1), p.250-250, Article 250

2020

Volltextzugriff (PDF)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Arthritis research & therapy, 2019-12, Vol.21 (1), p.272-11, Article 272

2019

Volltextzugriff (PDF)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Arthritis research & therapy, 2020-04, Vol.22 (1), p.70-11, Article 70

2020

Volltextzugriff (PDF)

Review: The Utility of Magnetic Resonance Imaging for Assessing Structural Damage in Randomized Controlled Trials in Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2013-10, Vol.65 (10), p.2513-2523

American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging Group and Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working Group

2013

Volltextzugriff (PDF)

Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis

Expert review of clinical immunology, 2022-03, Vol.18 (3), p.193-205

Strand, Vibeke

2022

Volltextzugriff (PDF)

Randomized controlled trial design in rheumatoid arthritis: the past decade

Arthritis research & therapy, 2009-01, Vol.11 (1), p.205-205

2009

Volltextzugriff (PDF)

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Journal of rheumatology, 2003-12, Vol.30 (12), p.2563

2003

Volltextzugriff (PDF)

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study

Modern rheumatology, 2021-05, Vol.31 (3), p.534-542

2021

Volltextzugriff (PDF)

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial

Journal of rheumatology, 2008-01, Vol.35 (1), p.41

2008

Volltextzugriff (PDF)

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis

Journal of rheumatology, 2005-04, Vol.32 (4), p.590

2005

Volltextzugriff (PDF)

Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis

Journal of rheumatology, 2003-06, Vol.30 (6), p.1182

2003

Volltextzugriff (PDF)

Mechanism of Action for Leflunomide in Rheumatoid Arthritis

Clinical Immunology, 1999-12, Vol.93 (3), p.198-208

1999

Volltextzugriff (PDF)

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2020-10, Vol.72 (10), p.1607-1620

2020

Volltextzugriff (PDF)

Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies

Rheumatology (Oxford, England), 2017-01, Vol.56 (1), p.46-57

2017

Volltextzugriff (PDF)

Newer Biological Agents in Rheumatoid Arthritis: Impact on Health-Related Quality of Life and Productivity

Drugs (New York, N.Y.), 2010-01, Vol.70 (2), p.121-145

2010

Volltextzugriff (PDF)

Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort

The American journal of medicine, 2008-06, Vol.121 (6), p.532-538

2008

Volltextzugriff (PDF)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

Journal of managed care & specialty pharmacy, 2018-04, Vol.24 (4), p.344-352

2018

Volltextzugriff (PDF)

25 years of biologic DMARDs in rheumatology

Nature reviews. Rheumatology, 2023-12, Vol.19 (12), p.761-766

2023

Volltextzugriff (PDF)

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE

Rheumatology (Oxford, England), 2021-12, Vol.60 (12), p.5583-5594

2021

Volltextzugriff (PDF)

Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis

Journal of rheumatology, 2005-08, Vol.32 (8), p.1620

2005

Volltextzugriff (PDF)

Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group

Journal of rheumatology, 2006-07, Vol.33 (7), p.1403

2006

Volltextzugriff (PDF)

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Arthritis research & therapy, 2015-12, Vol.17 (362), p.362-362, Article 362

2015

Volltextzugriff (PDF)

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

Annals of the rheumatic diseases, 2012-07, Vol.71 (7), p.1143-1150

2012

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Aktive Filter

ThemaArthritis, Rheumatoid - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(93)

Sprache

Englisch
(93)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(93)
Life Sciences & Biomedicine
(81)
Science & Technology
(81)
Rheumatology
(70)
Rheumatoid Arthritis
(60)
Treatment Outcome
(58)
Antirheumatic Agents - Therapeutic Use
(53)
Female
(50)
Male
(48)
Middle Aged
(46)
Adult
(36)
Aged
(28)
Biological And Medical Sciences
(28)
Drug Therapy, Combination
(28)
Medical Sciences
(28)
Methotrexate - Therapeutic Use
(23)
Quality Of Life
(23)
Severity Of Illness Index
(23)
Diseases Of The Osteoarticular System
(21)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Review: The Utility of Magnetic Resonance Imaging for Assessing Structural Damage in Randomized Controlled Trials in Rheumatoid Arthritis

Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis

Randomized controlled trial design in rheumatoid arthritis: the past decade

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis

Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis

Mechanism of Action for Leflunomide in Rheumatoid Arthritis

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial

Newer Biological Agents in Rheumatoid Arthritis: Impact on Health-Related Quality of Life and Productivity

Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

25 years of biologic DMARDs in rheumatology

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE

Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis

Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

Aktive Filter

Suchergebnisse filtern